Lingbo Biotech is focused on developing and industrializing small‑diameter bioartificial blood vessel technology. Its core products are biologic small‑caliber vascular grafts intended for cardiac bypass, dialysis access and peripheral vascular applications. The company recently completed an A+ financing round of several tens of millions of RMB. Proceeds from the round will be used to advance clinical development of existing products and to develop a new coronary artery bypass graft indication. Lingbo intends to accelerate multiple preclinical research programs and to push forward R&D and innovation in the regenerative medicine field. Lingbo Bio develops small‑diameter bioartificial vascular grafts aimed at clinical use. The company seeks to industrialize small‑diameter bioartificial blood vessel technology for surgical and vascular-disease applications. Its products target patients needing coronary artery bypass grafting, hemodialysis access, and peripheral vascular procedures. The firm emphasizes translating bioengineered vascular solutions into commercial medical devices. The article notes a recent financing event indicating investor confidence to support further development and commercialization efforts. No operating metrics (revenue or user numbers) are disclosed in the article.

Total raised

$14M

Funding rounds

2

Latest round

Series A

Latest activity

Nov 2023